Profile of brivaracetam and its potential in the treatment of epilepsy

Edoardo Ferlazzo1,2
Emilio Russo3
Laura Mumoli1
Chiara Sueri2
Sara Gasparini1,2
Caterina Palleria3
Angelo Labate1
Antonio Gambardella1
Giovambattista De Sarro2
Umberto Aguglia1,2

1Department of Medical and Surgical Sciences, Magna Græcia University, Catanzaro, 2Regional Epilepsy Centre, Bianchi-Melacrinio-Morelli Hospital, Reggio Calabria, 3Institute of Pharmacology, Magna Græcia University, Catanzaro, Italy

Abstract: Brivaracetam (BRV) (UCB 34714) is currently under review by the US Food and Drug Administration and European Medicines Agency for approval as an add-on treatment for adult patients with partial seizures. Similar to levetiracetam (LEV), BRV acts as a high-affinity ligand of the synaptic vesicle protein 2A, however, it has been shown to be 10- to 30-fold more potent than LEV. Moreover, BRV does not share the LEV inhibitory activity on the high voltage Ca2+ channels and AMPA receptors, and it has been reported to act as a partial antagonist on neuronal voltage-gated sodium channels. The pharmacokinetic profile of BRV is favorable and linear, and it undergoes an extensive metabolism into inactive compounds, mainly through the hydrolysis of its acetamide group. Furthermore, it does not significantly interact with other antiepileptic drugs and more than 95% is excreted through the urine, with an unchanged fraction of 8%–11%. BRV has a half-life of approximately 8–9 hours and it is usually given twice daily.

To date, a wide range of experimental studies have reported the effectiveness of BRV with regards to partial and generalized seizures. In humans, six randomized, placebo-controlled trials and two meta-analyses highlighted the efficacy, or good tolerability, of BRV as an add-on treatment for patients with uncontrolled partial seizures. A wide dose range of BRV has been evaluated in those trials (5–200 mg), but the most suitable for clinical use appears to be 50–100 mg/day. The most common adverse reactions to BRV are mild to moderate, transient, often improve during the course of the treatment, and mainly consist of central nervous system symptoms, such as fatigue, dizziness, and somnolence. The aim of this paper is to critically review the literature data regarding experimental animal models and clinical trials on BRV, and to define its potential usefulness for the clinicians who manage patients with epilepsy.

Keywords: seizures, animal, therapy, drug, antiepileptic

Introduction

Although the administration of antiepileptic drugs (AEDs) allows freedom from seizures in approximately 75% of patients with epilepsy, the occurrence of adverse drug reactions (ADR) is still responsible for poor compliance as well as the discontinuation of the therapy in up to 25% of patients before having reached the effective dose amount. Therefore, this has led to growing costs in clinical management.1,2

During the past few decades, research has been focused on the development of AEDs that have a more favorable pharmacological and pharmacodynamic profile. The possibility that antiepileptic efficacy can be reached through the modulation of neuronal hyperexcitability and, in particular, the effect on the synaptic vesicle protein 2A (SV2A)3 has recently raised experts’ interest. Levetiracetam (LEV) is the first molecule with this target and it represents the ancestor from which several racetam analogs have been subsequently developed.4 Brivaracetam (BRV) (2S)-2-[(4R)-2-oxo-4-propylpyrrolidinyl]-butanamide is a n-propyl analog of LEV,3 and its selectivity to SV2A, as well as its potency, have been demonstrated to be greater than those shown by LEV. According
to the experimental conditions, its potency for example, can be 10- to 30-fold higher than that of LEV.\textsuperscript{6,7} This article aims to critically review the literature regarding experimental animal models and clinical trials on BRV, and to define its potential usefulness for the clinicians who manage patients with epilepsy.

**Methods**

**Review of the literature**

References were identified by searching PubMed for articles published prior to October 2015, with the terms “brivaracetam” in combination with “seizures”, “epilepsy”, and “animal” being searched. Studies were also identified through searches within the authors’ own files and one abstract was also included in this revision. The selection criteria included newness, importance, originality, quality, and relevance to the scope of this review.

**Statistical analysis**

To describe efficacy and tolerability of BRV across different studies, categorical variables were described as percentages. Differences between groups (BRV and placebo-treated groups) were assessed using Fisher’s exact test. The critical P-value was set at 0.05.

**Pharmacodynamics of BRV and experiments on animal models of epilepsy**

BRV action on SV2A has been extensively tested. The SV2A protein is involved in neurotransmission by playing a role in the regulation of normal synaptic vesicle cycling and of neurotransmitter release.\textsuperscript{4,8} Even though many aspects of this type of mechanism need further clarification, the association between SV2A binding and an anticonvulsant effect has been demonstrated in experimental studies.\textsuperscript{8}

According to preclinical trials on animal models of both partial and generalized epilepsy, BRV demonstrates a higher potency and efficacy when compared to LEV.\textsuperscript{9,10} More precisely, in fully amygdala-kindled rats, BRV can determine a significant decrease in motor-seizure severity at the dosage of 21.2 mg/kg, while LEV shows analogous responses at the dose of 170 mg/kg. Moreover, a greater dose of BRV (212.3 mg/kg) is responsible for a significant decrease of the after-discharge duration, which is an effect that can be observed with LEV exclusively for dosages of 1,700 mg/kg or higher.\textsuperscript{9,10} Even in those mice that are resistant to phenytoin (ED50 68.3 mg/kg, ip), BRV was shown to be effective against both partial and generalized seizures.\textsuperscript{9,11}

As can be demonstrated by its acute dosing in audiogenic mice, BRV can cross the blood–brain barrier more easily than LEV. This implies a shorter latency of action, which may prove to be a clinically relevant result in the treatment of emergencies such as status epilepticus or cluster seizures.\textsuperscript{10} Furthermore, Detrait et al reported the effectiveness of BRV on kindled seizures that are relevantly modulated for seizure threshold and severity.\textsuperscript{12}

In a work evaluating the rapid kindling model in P14, P21, P28, and P60 rats, a 100 mg/kg dose of BRV succeeded in determining a significant increase in the after-discharge threshold at all ages, while the same drug at the dosage of 10 mg/kg was effective in P60, P28, and P21 rats only.\textsuperscript{13} Data regarding the reduction of the after-discharge duration indicate that 10 and 100 mg/kg doses of BRV are significantly effective at P60, whereas only the 100 mg/kg dose is effective at P21. At P60, the administration of BRV implies a higher number of stimulations to reach stage 4–5 seizures in a dose-dependent manner. Similarly, at P28 and P21, the administration of BRV determines the almost complete disappearance of stage 4–5 seizures, and requires an increased number of stimulations to evoke stage 4–5 seizures in a dose-dependent modality.\textsuperscript{13}

Furthermore, in a model of self-sustained status epilepticus, evoked by the stimulation of the perforant path, BRV demonstrated a synergic action with diazepam in decreasing the seizures’ duration.\textsuperscript{14} In agreement to such data, BRV (0.3 mg/kg) has recently been shown to have higher anti-seizure and antmyoclonic activity, when compared to LEV (3 mg/kg) in an animal model of post-hypoxic myoclonus.\textsuperscript{15}

Noteworthily, growing evidence indicates that in transgenic Alzheimer’s disease mice, BRV may not only play a role similar to that of ethosuximide with regards to spike-wave discharges, but it may also be effective in contrasting memory deterioration. Therefore, this new AED potentially shows an extended profile of action.\textsuperscript{16}

Additionally to its role in the SV2A blockade, BRV shares with other AEDs a potential, but still debated inhibitory effect on neuronal voltage-gated sodium channels, by acting as a partial antagonist.\textsuperscript{17–19}

**Pharmacokinetics of BRV**

The pharmacokinetic profile of BRV has been evaluated in healthy adult volunteers, the elderly, patients with epilepsy, and patients with hepatic or renal dysfunction.\textsuperscript{20–24} The drug exhibits favorable pharmacokinetic properties due to its linear and predictable profile, with low inter-subject variability and close to 100% bioavailability.\textsuperscript{11,20–22} The pharmacokinetic
differences in elderly patients, as compared to healthy volunteers, are not relevant and therefore dose adjustment does not seem to be required.  

Following oral administration, BRV is quickly absorbed at a gastrointestinal level with a linear and dose-dependent profile, and it is unaffected by the presence of food.  

The distribution volume of BRV is close to the total body water content (Vz = 0.5 L/kg) and it is weakly bound (17.5%) to plasma proteins. Terminal half-life is approximately 8–9 hours and BRV is usually administered twice daily in equal doses.  

BRV undergoes an extensive metabolism into three pharmacologically inactive compounds (UCB data files) and more than 95% is excreted through the urine with an unchanged fraction of 8%–11%. The main metabolic pathway consists of the hydrolysis of BRV’s acetamide group, leading to the formation of an acid metabolite (BRV-AC; 34.2% of the radiolabeled urinary dose). A smaller proportion of the drug is converted by the cytochrome P450 2C19 into a hydroxy metabolite (BRV-OH; 15.9% of the urinary dose). From the participation of both of these pathways, a hydroxyacid metabolite is produced (15.2% of the dose in the urine).  

Table 1 Six randomized, placebo-controlled trials of adjunctive BRV in patients with uncontrolled seizures

<table>
<thead>
<tr>
<th>Trial</th>
<th>ITT population (seizure type)</th>
<th>Brivaracetam range</th>
<th>Responder rates ≥ 50% for PBO and BRV</th>
</tr>
</thead>
<tbody>
<tr>
<td>French et al.27</td>
<td>BRV 154 (partial)</td>
<td>5–50 mg/day</td>
<td>16.7% for PBO</td>
</tr>
<tr>
<td></td>
<td>PBO 54 (partial)</td>
<td></td>
<td>32.0% for BRV 5 mg/day*</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>44.2% for BRV 20 mg/day*</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>55.8% for BRV 50 mg/day*</td>
</tr>
<tr>
<td>Van Paesschen et al.28</td>
<td>BRV 105 (partial)</td>
<td>50–150 mg/day</td>
<td>17.3% for PBO</td>
</tr>
<tr>
<td></td>
<td>PBO 52 (partial)</td>
<td></td>
<td>35.8% for BRV 50 mg/day*</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>30.8% for BRV 150 mg/day</td>
</tr>
<tr>
<td>Ryvlin et al.29</td>
<td>BRV 298 (partial)</td>
<td>20–100 mg/day</td>
<td>20.0% for PBO</td>
</tr>
<tr>
<td></td>
<td>PBO 100 (partial)</td>
<td></td>
<td>27.3% for BRV 20 mg/day</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>27.3% for BRV 50 mg/day</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>36.0% for BRV 100 mg/day*</td>
</tr>
<tr>
<td>Biton et al.30</td>
<td>BRV 298 (partial)</td>
<td>5–50 mg/day</td>
<td>16.7% for PBO</td>
</tr>
<tr>
<td></td>
<td>PBO 98 (partial)</td>
<td></td>
<td>21.9% for BRV 5 mg/day</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>23.2% for BRV 20 mg/day</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>32.7% for BRV 50 mg/day*</td>
</tr>
<tr>
<td>Kwan et al.31</td>
<td>BRV 359 (323 partial; 36 generalized)</td>
<td>Flexible doses</td>
<td>16.7% for PBO</td>
</tr>
<tr>
<td></td>
<td>PBO 121 (108 focal; 13 generalized)</td>
<td>20–150 mg/day</td>
<td>30.3% in BRV group with partial seizures*</td>
</tr>
<tr>
<td>Klein et al.32</td>
<td>BRV 501 (partial)</td>
<td>100–200 mg/day</td>
<td>16.7% for PBO</td>
</tr>
<tr>
<td></td>
<td>PBO 259 (partial)</td>
<td></td>
<td>38.9% for BRV 100 mg/day*</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>37.8% for BRV 200 mg/day*</td>
</tr>
</tbody>
</table>


Abbreviations: BRV, brivaracetam; ITT, intention-to-treat; NR, not reported data; PBO, placebo.
administered dose of BRV (ranging from 5–50 mg/day), but was statistically significant only for BRV 50 mg/day (9.8% for BRV 5 mg/day \( P=0.240 \); 14.9% for BRV 20 mg/day \( P=0.062 \); 22.1% for BRV 50 mg/day \( P=0.004 \)). Seizure freedom rates during an observational treatment period of 7 weeks were 1.9% with placebo, 8.0% with BRV 5 mg/day, 7.7% with BRV 20 mg/day, and 7.7% with BRV 50 mg/day.

In the Van Paesschen et al trial (Table 1), primary efficacy analysis did not reach statistical significance. In particular, the percent reduction in baseline-adjusted partial seizure frequency/week over placebo during the 7-week maintenance period over placebo was not significant in those treated with BRV 50 mg/day (14.7% reduction, \( P=0.093 \)), or with BRV 150 mg/day (13.6% reduction, \( P=0.124 \)). However, a significant difference over placebo for the same outcome measure was reported during the 10-week total treatment period for the BRV 50 mg/day group (17.7% reduction, \( P=0.026 \)), as well as for the BRV 150 mg/day group (16.3% reduction, \( P=0.043 \)). Seizure freedom was reached by a total of nine patients (five patients [9.4%] with BRV 50 mg/day; three patients [5.8%] with BRV 150 mg/day; and one patient [1.9%] with placebo). BRV at a daily dose of 100 mg/day showed efficacy in the trial by Ryvlin et al (Table 1). The percentage reduction over placebo in the baseline-adjusted seizure frequency per week was 6.8% in those treated with BRV 20 mg/day (\( P=0.239 \)), 6.5% in those treated with BRV 50 mg/day (\( P=0.261 \)), and 11.7% in those treated with BRV 100 mg/day (\( P=0.037 \)). Seizure freedom was achieved by two (2%) patients treated with BRV 20 mg/day, no patients who were treated with BRV 50 mg/day, four (4%) patients treated with BRV 100 mg/day, and no patients who were treated with the placebo.

The trial byBiton et al highlighted that BRV has a dose-related efficacy. In particular, the median reduction in the percentage over placebo from the baseline of seizure frequency per week was -0.9% (\( P=0.885 \)) for BRV 5 mg/day, 4.1% (\( P=0.492 \)) for BRV 20 mg/day, and 12.8% (\( P=0.025 \)) for BRV 50 mg/day. Seizure freedom was reached by a total of six patients (no patients treated with the placebo, one [1.1%] patient treated with BRV 5 mg/day, one [1.1%] patient treated with BRV 20 mg/day, and four [4.0%] patients treated with BRV 50 mg/day).

The trial carried out by Kwan et al (Table 1) tested BRV at individually-tailored doses ranging from 20–150 mg/day in patients suffering from either partial or generalized refractory seizures. The baseline-adjusted percentage reduction over placebo of the partial seizure frequency per week was not significant in patients with partial seizures (7.3%; \( P=0.125 \)). Five (1.5%) patients with partial seizures were seizure free during the treatment period.

The trial by Klein et al (Table 1) showed a significant efficacy of BRV at 100 and 200 mg/day, as compared to the placebo with a median percentage decrement over placebo in a 28-day adjusted seizure frequency of 22.8% when using BRV 100 mg/day (\( P<0.001 \)), and of 23.2% when using BRV 200 mg/day (\( P<0.001 \)). During the treatment period, 25 patients reached seizure freedom (two [0.8%] patients treated with placebo; 13 [5.2%] patients treated with BRV 100 mg/day \( P=0.003 \) compared to placebo); and ten [4.0%] patients treated with BRV 200 mg/day \( P=0.019 \) compared to placebo).

In five of these trials, the continuation of LEV as allowed. It seems that patients with a concomitant use of LEV did not respond as well to BRV in comparison to the patients not currently taking LEV, suggesting that its concomitant use may decrease BRV efficacy. Due to the small number of patients taking LEV in these trials, further studies should be performed to evaluate this pharmacodynamic interaction.

**Effect of BRV on generalized seizures**

In analogy with LEV, BRV may find an indication for generalized epilepsies.

The only trial evaluating the efficacy of BRV on generalized seizures was conducted by Kwan et al. In this study, 49 patients had generalized seizures, mostly tonic-clonic (30 patients), absences (14 patients), and myoclonic (14 patients). Two (5.6%) patients with generalized seizures were seizure free during the treatment period. The number of generalized seizure days per week reduced from 1.42 at baseline to 0.63 in the BRV-treated patients (n=36), and from 1.47 at baseline to 1.26 in the placebo group (n=13). Moreover, the median percentage reduction from baseline in generalized seizure days per week was 42.6% in the BRV group versus 20.7% in the placebo group (statistical significance not shown).

In a Phase IIA, single blind, placebo-controlled study evaluating 18 patients with idiopathic generalized epilepsies and photosensitivity, BRV was found to have the ability to suppress generalized photoparoxysmal responses (PPR) on electroencephalogram. No patients achieved PPR abolishment with the placebo, whereas 14 (78%) patients experienced complete abolishment with BRV in this study. Among the evaluated dosages (10, 20, 40, or 80 mg/day), 80 mg was the most effective, resulting in long-lasting abolishment of the PPR.
Further studies are needed to confirm the efficacy of BRV in patients with generalized seizures.

Effect of BRV in progressive myoclonic epilepsies

BRV, as compared to LEV, may have potential in the management of progressive myoclonic epilepsies.\(^{38,39}\) However, two randomized, placebo-controlled trials assessing the efficacy and tolerability of BRV (5–150 mg/day) as an add-on therapy in Unverricht-Lundborg disease (the most frequent and less severe form of progressive myoclonic epilepsies),\(^{40,41}\) did not report a significant improvement of myoclonus.\(^{42}\) These trials had some limitations, especially the small sample size and the unpredictable inter- and intra-subject variability of myoclonus in Unverricht-Lundborg disease. Moreover, patients were allowed to receive LEV.\(^{42}\) Due to these reasons, further studies evaluating BRV in progressive myoclonic epilepsies are needed.

Safety profile of BRV

BRV has been shown to have a favorable safety profile, as the side effects reported in association with its administration are mild to moderate and usually do not affect the compliance to the treatment (Table 2). In actuality, a dose of 20–150 mg/day has shown to be well tolerated, with a discontinuation rate of 6.1% due to ADRs, in comparison to the 5.0% rate has shown to be well tolerated, with a discontinuation rate of 6.1% due to ADRs, in comparison to the 5.0% rate reported in the placebo group.\(^{31}\) The tolerability of BRV is even more impressive when considering that its side effects appear to be transient and to decrease in intensity during the course of treatment. In adult patients, the main ADRs are represented by symptoms of the central nervous system consisting of sedation, fatigue, and dizziness (Table 2).\(^{21}\) The severity of the somnolence induced by BRV as evaluated by psychometric tests is dose-related, becoming clear for a dosage $\geq$600 mg with symptoms such as decreased attention, motor control, and alertness manifesting.\(^{21}\) The type and the intensity of ADRs is not affected by food intake.\(^{21}\) Even when prescribed at very high doses (up to 800 mg/day), BRV does not affect cardiac function.\(^{43}\)

Twice-daily administration of BRV reduces the peak-to-trough fluctuations of plasma concentrations and minimizes the adverse reactions, as observed in healthy males.\(^{21}\)

Experimental studies on animals revealed the absence of any side effects of BRV on fertility and pregnancy (BRV at 400 mg/kg/day), or fetal development (BRV at 600 mg/day).\(^{25}\) However, the effects of treatment with BRV on fertility, or its eventual teratogenicity, are still to be evaluated in humans.

The aforementioned six randomized, placebo-controlled clinical trials included 2,403 patients recruited by intention-to-treat analysis (1,715 patients treated with BRV and 688 patients treated with placebo).\(^{27–32}\) The percentage of patients complaining of at least one side effect was significantly higher in those taking BRV (66.1% in the BRV group and 60.5% in the placebo group) as observed in healthy males.\(^{21}\)

Table 2 Most common adverse effects of BRV in six randomized, placebo-controlled clinical trials

<table>
<thead>
<tr>
<th>Trial</th>
<th>Headache</th>
<th>Somnolence</th>
<th>Fatigue</th>
<th>Dizziness</th>
<th>Gastrointestinal disturbance</th>
</tr>
</thead>
<tbody>
<tr>
<td>French et al(^{27})</td>
<td>BRV 5: 8%</td>
<td>BRV 5: 2%</td>
<td>BRV 5: 0%</td>
<td>BRV 5: 2%</td>
<td>NR</td>
</tr>
<tr>
<td></td>
<td>BRV 20: 3.8%</td>
<td>BRV 20: 5.8%</td>
<td>BRV 20: 5.8%</td>
<td>BRV 20: 0%</td>
<td>BRV 20: 0%</td>
</tr>
<tr>
<td></td>
<td>BRV 50: 1.9%</td>
<td>BRV 50: 5.8%</td>
<td>BRV 50: 5.8%</td>
<td>BRV 50: 7.7%</td>
<td>BRV 50: 7.7%</td>
</tr>
<tr>
<td></td>
<td>PBO: 7.4%</td>
<td>PBO: 7.4%</td>
<td>PBO: 3.7%</td>
<td>PBO: 5.6%</td>
<td></td>
</tr>
<tr>
<td>Van Paesschen et al(^{28})</td>
<td>BRV 50: 15.1%</td>
<td>BRV 50: 9.4%</td>
<td>BRV 50: 13.2%</td>
<td>BRV 50: 3.8%</td>
<td>BRV 50: 9.4%</td>
</tr>
<tr>
<td></td>
<td>BRV 150: 7.7%</td>
<td>BRV 150: 5.8%</td>
<td>BRV 150: 5.8%</td>
<td>BRV 150: 9.6%</td>
<td>BRV 150: 19.3%</td>
</tr>
<tr>
<td></td>
<td>PBO: 7.7%</td>
<td>PBO: 5.8%</td>
<td>PBO: 7.7%</td>
<td>PBO: 5.8%</td>
<td>PBO: 15.3%</td>
</tr>
<tr>
<td>Ryvlin et al(^{29})</td>
<td>BRV 20: 14.1%</td>
<td>BRV 20: 8.1%</td>
<td>BRV 20: 3%</td>
<td>BRV 20: 5.1%</td>
<td>BRV 20: 0%</td>
</tr>
<tr>
<td></td>
<td>BRV 50: 18.2%</td>
<td>BRV 50: 6.1%</td>
<td>BRV 50: 4%</td>
<td>BRV 50: 7.1%</td>
<td>BRV 50: 1%</td>
</tr>
<tr>
<td></td>
<td>BRV 100: 9%</td>
<td>BRV 100: 8%</td>
<td>BRV 100: 8%</td>
<td>BRV 100: 5%</td>
<td>BRV 100: 6%</td>
</tr>
<tr>
<td></td>
<td>PBO: 9%</td>
<td>PBO: 6%</td>
<td>PBO: 2%</td>
<td>PBO: 8%</td>
<td>PBO: 4%</td>
</tr>
<tr>
<td>Biton et al(^{30})</td>
<td>BRV 5: 11.3%</td>
<td>BRV 5: 14.4%</td>
<td>BRV 5: 3.1%</td>
<td>BRV 5: 12.4%</td>
<td>BRV 5: 11.3%</td>
</tr>
<tr>
<td></td>
<td>BRV 20: 6%</td>
<td>BRV 20: 14%</td>
<td>BRV 20: 13%</td>
<td>BRV 20: 14%</td>
<td>BRV 20: 12%</td>
</tr>
<tr>
<td></td>
<td>BRV 50: 13%</td>
<td>BRV 50: 16.8%</td>
<td>BRV 50: 9.9%</td>
<td>BRV 50: 15.8%</td>
<td>BRV 50: 16.8%</td>
</tr>
<tr>
<td></td>
<td>PBO: 14.3%</td>
<td>PBO: 7.1%</td>
<td>PBO: 2%</td>
<td>PBO: 9.2%</td>
<td>PBO: 6.1%</td>
</tr>
<tr>
<td>Kwan et al(^{31})</td>
<td>BRV: 14.2%</td>
<td>BRV: 14.1%</td>
<td>BRV: 7.8%</td>
<td>BRV: 8.6%</td>
<td>BRV: 5.6%</td>
</tr>
<tr>
<td></td>
<td>PBO: 19.8%</td>
<td>PBO: 4.1%</td>
<td>PBO: 4.1%</td>
<td>PBO: 5.8%</td>
<td>PBO: 8.3%</td>
</tr>
<tr>
<td>Klein et al(^{32})</td>
<td>BRV 100: 6.7%</td>
<td>BRV 100: 19.4%</td>
<td>BRV 100: 7.5%</td>
<td>BRV 100: 10.3%</td>
<td>NR</td>
</tr>
<tr>
<td></td>
<td>BRV 200: 8.0%</td>
<td>BRV 200: 16.8%</td>
<td>BRV 200: 11.6%</td>
<td>BRV 200: 14.4%</td>
<td></td>
</tr>
<tr>
<td></td>
<td>PBO: 8.4%</td>
<td>PBO: 7.7%</td>
<td>PBO: 3.8%</td>
<td>PBO: 5%</td>
<td></td>
</tr>
</tbody>
</table>

Notes: Data from these studies.\(^{27–32}\) Dose for BRV is mg/day.
Abbreviations: BRV, brivaracetam; NR, not reported; PBO, placebo.
the placebo group, \( P=0.008 \). However, the majority of the reactions were mild or moderate, and the discontinuation rate, secondary to adverse effects, was very low and similar in both groups (6.0\% in the BRV group and 4.0\% in the placebo group, \( P=0.06 \)). Serious ADRs were rarely observed in a similar proportion in both groups (2.9\% in patients treated with BRV and 4.4\% in patients treated with placebo, \( P=0.20 \)). The following single ADRs were observed to be significantly more frequent in patients treated with BRV, compared to those patients on the placebo: dizziness (10\% vs 6.3\%, \( P=0.002 \)), fatigue (7.7\% vs 3.6\%, \( P<0.001 \)), and somnolence (12\% vs 6.6\%, \( P<0.001 \)). Irritability was documented in only three trials among a small percentage of patients (3\% in the BRV group and 1\% in the placebo group, \( P=0.36 \)).

The eventual negative side effects on sexual functioning, described for LEV as well as different new AEDs,\textsuperscript{44-46} also need to be investigated for BRV.

**Drug interactions**

Therapy with BRV does not significantly affect the plasma concentrations of other AEDs.\textsuperscript{47} Nevertheless, carbamazepine blood levels appear to be slightly decreased in case of concurrent intake of BRV (400 mg/day). At the same time, the blood concentration of carbamazepine-epoxide increases in a dose-dependent way\textsuperscript{25,48} as a result of the negative influence of BRV on epoxide hydrolase, which is the enzyme responsible for the conversion of carbamazepine-epoxide into carbamazepine-diol.\textsuperscript{48} While therapeutic doses of BRV (100 mg/day) do not affect oral contraceptive efficacy, high doses of BRV (400 mg/day) may slightly decrease serum levels of ethinylestradiol and levonorgestrel, without any impact on ovulation.\textsuperscript{49}

**Conclusion**

BRV represents a new generation of AED, with an action partially overlapping with that of LEV, and a possible inhibitory influence on voltage-gated sodium channels which is a mechanism that is also observed in several other AEDs.\textsuperscript{30} On this basis, it is possible to presume that BRV is at least as effective as LEV, indicating that it is a reasonable adjunctive therapy in patients with partial epilepsy. The efficacy or tolerability of BRV on drug-resistant partial seizures has actually been evaluated and confirmed by six randomized, placebo-controlled trials\textsuperscript{27-31} and by two recent meta-analyses.\textsuperscript{33,34} A wide range of BRV dosages has been evaluated in these trials (5–200 mg/day), but the most suitable for clinical use appears to be 50–100 mg/day. Further studies are needed to evaluate BRV efficacy in generalized seizures and to investigate the long-term efficacy and safety of this drug.

**Disclosure**

E Ferlazzo received speaker fees from UCB. E Russo received speaker fees from Almirall, Eisai, and Lundbeck. A Gambardella received speaker fees from UCB, Eisai, and Novartis. A Labate received speaker fees from UCB. The authors report no other conflicts of interest in this work.

**References**